Recursive Superintelligence, founded by former Google, Meta and OpenAI researchers, is part of a growing effort to automate ...

If Python developers have one consistent gripe about their beloved language, it tends to be this: Why is it so hard to take a Python program and deploy it as a standalone artifact, the way C, C++, ...

Meta's new hyperagent framework breaks the AI "maintenance wall," allowing systems to autonomously rewrite their own logic and scale across tasks without constant human engineering.

Florida's Python Elimination Program pays certified hunters to remove the invasive snakes from the Everglades. Burmese pythons have caused a severe decline in native small mammal populations in South ...

I wore the world's first HDR10 smart glasses TCL's new E Ink tablet beats the Remarkable and Kindle Anker's new charger is one of the most unique I've ever seen Best laptop cooling pads Best flip ...

The Anthropic co-founder Jack Clark tells Ezra Klein what he sees coming in the new era of A.I. agents. This is an edited transcript of “The Ezra Klein Show.” You can listen to the episode wherever ...

I'm a Fitness & Nutrition writer for CNET who enjoys reviewing the latest fitness gadgets, testing out activewear and sneakers, as well as debunking wellness/fitness myths. In my free time I enjoy ...

Building strength and muscle comes with huge payoffs for health and longevity, but most Americans still don't lift weights or regularly practice any muscle-strengthening activity. Why? People often ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Support for Windows 10 22H2 officially ended earlier this week on October 14th, and one day later, on October 15th, registration for Extended Security Updates (ESU) was finally activated. This means ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...